Aldoxorubicin More Effective Than Doxorubicin in STS
Aldoxorubicin (formerly INNO-206) has demonstrated response rates that culminated in a higher incidence of stable disease when compared with doxorubicin as a first-line treatment for patients with advanced soft tissue sarcomas
PARP Inhibitors Reemerge as Treatment for Serous Ovarian Cancer
The genomic instability inherent in serous ovarian cancer poses treatment challenges, but it also represents a target that can be exploited through the use of PARP inhibitors
ALK-Positive Criteria for Determining Crizotinib Use May Fall Short
The criteria that are presently used to determine whether patients with non-small cell lung cancer (NSCLC) may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug, researchers report.
Subgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2
New analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression- free survival (PFS) than placebo and exemestane in several previously unstudied patient subgroups.
Stem Cell Transplantation May Impair Sexual Health
Both men and women report a significant decline in sexual satisfaction after hematopoietic cell transplantation (HCT) that is sustained at 3-year follow-up
Analysis Finds Cancer Care Coordination Increases Patient Satisfaction
An analysis of cancer care coordination over the last 30 years shows that the process offers many benefits to oncology patients, including fewer hospitalizations and visits to emergency departments and increased patient satisfaction with care.
Standardizing Palliative Care Referrals and Distress Assessment
In 2012, the American Society of Clinical Oncology (ASCO) recommended routinely offering palliative care to patients with metastatic cancer and uncontrolled symptoms to improve symptom control and quality of life and reduce caregiver burden.
Evidence-Based Guidelines Needed for Immunotherapy-Related Adverse Events
As more immunotherapies move from the bench to the bedside, oncology nurses need to develop a thorough understanding of how these treatments work, as well as how their adverse event profiles differ from those typically seen with traditional cytotoxic regimens
Preventing and Managing Treatment-Related Lymphedema
Cancer-related lymphedema can result from the cancer or its treatment. It is an accumulation of protein-rich fluid in an interstitial space which may be the result of surgical resection, lymph node dissection, or radiation therapy
Studies Demonstrate Potential of Immunomodulation as Therapeutic Target in Gynecologic Cancers
The "renaissance in immunology" is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand
Offering Durable Responses With Less Toxicity in Melanoma
The results emerging from the PD-1/PD-L1 trials mark a major step forward, noted Rajni Kannan, MN, RN, ANP, in a recent interview on the implications of this research for multiple cancers, including melanoma
Provenge Treatment Team Supports Patients Every Step of the Way
The FDA's approval in 2010 of sipuleucel-T (Provenge) marked a milestone in the treatment of men with advanced prostate cancer and ushered in an exciting new immunotherapeutic treatment approach.
Exploring the Leadership Role of Advanced Practice Provider Manager
In 2010, Smilow Cancer Hospital (SCH) at Yale New Haven and Yale Cancer Center (YCC) transitioned from a multisite cancer care delivery system that was both university- and hospitalbased to a new, state-of-the-art, 14-story comprehensive cancer center building.
Helping Patients to Manage Dermatologic Toxicities: An Interview With Kathryn Ciccolini, RN, BSN, OCN
Dermatologic adverse events (AEs) associated with anticancer therapies can be complex and are best managed with a proactive and holistic approach-one that takes into account not only the physical demands of the regimen itself, but also the many challenges that patients often face involving treatment adherence, quality of life, and psychosocial concerns.
Immunotherapy Poised to Transform Cancer Treatment
Immunotherapy has become an increasingly appealing therapeutic strategy for patients with cancer, with many late-stage clinical trials demonstrating overall survival (OS) advantages in melanoma and castration-resistant prostate cancer.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512